In ₹ Crore except Per Share Latest Annual	AMBUJACEM FY26	ACC FY26	ULTRACEMCO FY26	SHREECEM FY26	Peer Average
Valuation — at last close
P/E	18.52×	◆ 10.14×	40.25×	47.84×	32.74× -43%
P/B	1.48×	◆ 1.06×	4.30×	3.59×	2.98× -50%
EV/EBITDA	15.18×	◆ 7.16×	20.63×	16.47×	14.75× +3%
Market Cap	₹87,675 Cr	₹21,685 Cr	₹3.29L Cr	₹83,417 Cr	₹1.45L Cr -39%
Growth
Revenue CAGR 3Y	1.45%	5.34%	◆ 11.86%	5.47%	7.56% -81%
Revenue CAGR 5Y	7.02%	9.96%	◆ 14.63%	9.22%	11.27% -38%
Net Income CAGR 3Y	23.07%	◆ 34.15%	17.30%	11.28%	20.91% +10%
Revenue YoY (latest Q)	0.25%	-4.09%	18.81%	◆ 23.85%	12.86% -98%
Net Income YoY (latest Q)	-89.75%	-91.69%	◆ 21.28%	-14.96%	-28.46% -215%
Profitability
EBITDA Margin	16.08%	11.36%	19.23%	◆ 22.14%	17.58% -9%
Net Income Margin	◆ 13.87%	8.23%	9.25%	8.35%	8.61% +61%
Return on Common Equity	8.38%	10.93%	◆ 11.08%	7.78%	9.93% -16%
Return on Capital Employed	4.13%	8.83%	◆ 11.85%	7.81%	9.50% -57%
Return on Assets	6.61%	◆ 8.07%	5.95%	5.83%	6.62% 0%
Credit & Quality
Total Debt/Equity	◆ 0.00×	0.00×	0.28×	0.07×	0.12× -100%
Interest Coverage	13.28×	◆ 16.35×	6.61×	8.71×	10.56× +26%
Scale — latest FY
Revenue / Total Income	₹40,656 Cr	₹25,962 Cr	₹88,512 Cr	₹20,943 Cr	₹45,139 Cr -10%
Net Income	₹5,637 Cr	₹2,137 Cr	₹8,188 Cr	₹1,749 Cr	₹4,025 Cr +40%
Total Assets	₹89,607 Cr	₹27,525 Cr	₹1.41L Cr	₹31,476 Cr	₹66,792 Cr +34%
EPS	₹19.15	₹113.8	₹277.62	₹483.24	₹291.55 -93%
Book Value per Share	₹240.1	₹1,093.17	₹2,600.23	₹6,448.87	₹3,380.76 -93%

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.